Uniting the Power of Nanotechnology and Immunity for the Fight to Cancer and COVID-19
By developing novel combination immunotherapies utilizing our potent anti-tumor T cell activating nano-immunotherapy “T-ignite”, we challenge conquest of intractable solid cancer, especially “cold tumor”, where conventional therapies are not effective for. The same technology is being used for the development of a next generation SARS-CoV-2 nanoparticle vaccine.
- September 7, 2021 – United Immunity, uniting its proprietary nanotechnology and innate immunity to treat cold tumor and COVID-19, secured 5 Oku-yen (USD 4.6M) in the Series B financing. The Series B was led by the University of Tokyo Edge Capital Partners Co., Ltd. (UTEC) and KISCO Ltd.
- January 14, 2021 – United Immunity and Xyphos, an Astellas company, entered into a joint research agreement to discover next gen nano-immunotherapies.
- January 4, 2021 – Japan AMED decided to provide the company an R&D grant for our new program to develop a new T-ignite product for the treatment of advanced solid cancers.
- October 26, 2020 – A joint team of United Immunity, Kyoto University, and Nagasaki University published an article reporting a new animal model for the evaluation of immunogenicity of SARS-CoV-2 vaccines.
- July 31, 2020 – Japan AMED decided to provide the company an R&D grant for our new program to develop a next gen SARS-CoV-2 nanoparticle vaccine.
(Next page “Our Science and Technology”)